Thomas West is the Vice President of Pharmaceutical Development at Aprecia Pharmaceuticals, focusing on internal pipeline and partnership/licensing opportunities. For over 20 years he has held positions of escalating responsibility, applying 3D printing to the life sciences in start-up to development-stage companies. His experience includes diverse aspects of novel product and process development, regulatory strategy, intellectual property and market assessment. Example applications include rapidly disintegrating oral dosage forms, controlled-release oral and implantable dosage forms and synthetic bone graft substitutes. He is a co-inventor on numerous patents related to 3D printing and co-authored a book chapter outlining the development context for SPRITAM, the first 3D printed pharmaceutical product to receive US FDA approval. Mr West received his BSc and MSc degrees in Chemical Engineering from Rutgers University (NJ, US),
and is a registered patent agent.